Table 4.
Spearman correlation (ρ) between baseline continuous and categorical variables
| Baseline variables | 14-3-3η | 14-3-3η | 14-3-3η | Anti-CCP2 | Anti-CCP2-positive | RF | RF positive | Age (years) | Age ≥65 years | BMI ≥30 |
|---|---|---|---|---|---|---|---|---|---|---|
| ≥0.19 | ≥0.50 | |||||||||
| 14-3-3η | 1 | |||||||||
| 14-3-3η ≥ 0.19 | 0.865 *** | 1 | ||||||||
| 14-3-3η ≥ 0.50 | 0.833 *** | 0.808 *** | 1 | |||||||
| Anti-CCP2 | 0.529 *** | 0.515 *** | 0.530 *** | 1 | ||||||
| Anti-CCP2-positive | 0.529 *** | 0.524 *** | 0.539 *** | 0.849 *** | 1 | |||||
| RF | 0.716 *** | 0.659 *** | 0.731 *** | 0.624 *** | 0.638 *** | 1 | ||||
| RF positive | 0.669 *** | 0.616 *** | 0.679 *** | 0.616 *** | 0.661 *** | 0.927 *** | 1 | |||
| Anti-Sa positive | 0.409 *** | 0.413 *** | 0.437 *** | 0.527 *** | 0.519 *** | 0.500 *** | 0.481 *** | |||
| Age (years) | -0.140 * | -0.118 * | -0.087 | -0.033 | -0.085 | -0.069 | -0.104 | 1 | ||
| Age ≥65 years | -0.151 ** | -0.131 * | -0.103 | -0.040 | -0.095 | -0.071 | -0.099 | 0.836 *** | 1 | |
| BMI ≥30 | -0.028 | 0.042 | 0.007 | -0.031 | -0.013 | -0.014 | -0.039 | -0.06 | -0.024 | 1 |
| Gender (women vs men) | -0.031 | -0.034 | -0.074 | -0.010 | -0.033 | -0.044 | -0.030 | -0.158 ** | -0.072 | 0.000 |
| Symptom duration (months) | 0.119 * | 0.127 * | 0.122 * | 0.144 | 0.164 | 0.146 | 0.141 | -0.067 | -0.032 | -0.002 |
| Current smoker | 0.137 * | 0.075 | 0.110 * | -0.022 | 0.005 | 0.091 | 0.112 | -0.221 *** | -0.206 *** | -0.068 |
| M-HAQ | 0.024 | 0.009 | 0.000 | -0.030 | -0.064 | -0.024 | -0.053 | 0.112 * | 0.032 | 0.138 * |
| DAS28-CRP | 0.061 | 0.052 | 0.077 | 0.023 | -0.009 | 0.064 | 0.013 | 0.135 ** | 0.101 | 0.048 |
| SDAI | 0.041 | 0.033 | 0.067 | 0.009 | -0.024 | 0.050 | -0.006 | 0.112 ** | 0.089 | 0.02 |
| Pain | 0.012 | -0.004 | -0.011 | 0.029 | 0.003 | 0.051 | 0.043 | 0.011 | 0.014 | 0.124 * |
| ESR | 0.044 | 0.059 | 0.076 | 0.035 | 0.007 | 0.089 | 0.067 | 0.267 *** | 0.196 *** | 0.115 * |
| CRP | 0.000 | -0.011 | 0.023 | 0.014 | 0.021 | 0.015 | -0.009 | 0.151 ** | 0.091 | 0.091 |
| CRP >8 | -0.02 | -0.021 | 0.008 | 0.002 | 0.008 | -0.015 | -0.029 | 0.091 | 0.048 | 0.028 |
| SJC28 | 0.019 | 0.010 | 0.055 | -0.019 | -0.059 | 0.036 | 0.000 | 0.094 | 0.084 | -0.043 |
| TJC28 | 0.082 | 0.080 | 0.103 | 0.008 | -0.022 | 0.065 | 0.005 | 0.124 * | 0.102 | 0.009 |
| Total SvH score | 0.036 | 0.051 | 0.049 | 0.009 | 0.024 | 0.026 | -0.005 | 0.491 *** | 0.391 *** | 0.013 |
| SvH erosion score | 0.04 | 0.035 | 0.052 | 0.021 | 0.049 | 0.050 | 0.022 | 0.360 *** | 0.287 *** | 0.02 |
*p <0.05, **p <0.01, ***p <0.001. Anti-CCP2 antibodies against citrullinated peptides, second generation, RF rheumatoid factor, BMI body mass index, M-HAQ Modified Health Assessment Questionnaire, DAS28 Disease Activity Score in 28 joints, SDAI Simplified Disease Activity Score, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SJC swollen joint count, TJC tender joint count, SvH progression in the total Sharp score modified by van der Heijde